Condition: Metastatic Renal Cell Carcinoma · Radiotherapy · Sponsor: Centre Francois Baclesse
Every year, 12500 primary renal cell carcinoma (RCC) are diagnosed in France. Metastases occur in half of RCC patients. Management of metastatic RCC is based on systemic treatments (targeted therapies/immunotherapy). However, resistance to systemic treatment is frequent. In case of progression, usual therapeutic attitude is initiating another systemic therapy. Because of the emergence of resistant tumor clonal cells, some patients progress only on few sites while the rest of tumor burden is controlled. In this setting named oligoprogressive disease \[isolated progression of \<3-5 metastase(s)\], ablative treatments of these evolving metastatic sites could allow a disease control and a reduced risk of new metastases occurrence by tumor-cell reembolization. Such strategy is challenging to prolong ongoing systemic treatment and delay further lines. Although RCC was considered radioresistant and radiotherapy with conventional fractionation was mainly used for palliation of symptoms, stereotactic radiotherapy (SRT), by delivering high dose in one or few fractions, allows local control for about 90% of RCC metastases through various radiobiological pathways. Furthermore, some data suggest that high-dose focal irradiation of RCC could induce a systemic antitumor response mediated by immunologic effectors(1). This phenomenon ("abscopal effect") could be enhanced in patients under immunotherapy, including anti-PD1. Several retrospective studies and one non-randomized phase-II stud…
This description comes directly from the study's public registry record.
Nazim KALHADI, MD · + 332 31 45 50 50 · n.khalladi@baclesse.unicancer.fr
Jean-Michel GRELLARD · +33 2 31 45 50 50 · jm.grellard@baclesse.unicancer.fr
Always discuss trial participation with your own doctor first.
| Clinique Claude Bernard | Albi, France | Not Yet Recruiting |
| Institut de Cancérologie de l'Ouest | Angers, France | Recruiting |
| Institut Bergonié | Bordeaux, France | Not Yet Recruiting |
| Radiothérapie Bordeaux Nord Aquitaine | Bordeaux, France | Not Yet Recruiting |
| Centre François Baclesse | Caen, France | Recruiting |
| Centre Jean Perrin | Clermont-Ferrand, France | Not Yet Recruiting |
| CHU Henri Mondor | Créteil, France | Not Yet Recruiting |
| Centre Georges François LECLERC | Dijon, France | Not Yet Recruiting |
| Institut de cancérologie de Bourgogne (Dijon, Auxerre, Chalon sur Saône) | Dijon, France | Recruiting |
| CHD Vendée | La Roche-sur-Yon, France | Not Yet Recruiting |
| Centre de radiothérapie Guillaume le Conquérant | Le Havre, France | Not Yet Recruiting |
| Centre Oscar Lambret | Lille, France | Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04299646